<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="218839">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00235482</url>
  </required_header>
  <id_info>
    <org_study_id>PSX-X-02</org_study_id>
    <nct_id>NCT00235482</nct_id>
  </id_info>
  <brief_title>Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma</brief_title>
  <official_title>Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viralytics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viralytics</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of an injection of coxsackievirus A21
      into a melanoma tumour, and also to see if there is a tumour response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coxsackievirus A21, a naturally occurring enterovirus, has shown that in vivo it can infect
      and lyse melanoma. This study is to assess safety of a single intratumoural injection of the
      virus into an accessible subcutaneous melanoma metastasis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety profile of treatment, characterisation of adverse events</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy - clinical response of injected and non-injected tumours</measure>
  </secondary_outcome>
  <enrollment>3</enrollment>
  <condition>Malignant Melanoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coxsackievirus A21</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  stage IV melanoma (AJCC classification)

          -  minimum of 2 sc metastases

          -  failure or refusal of standard chemotherapy

          -  ECOG score of 0 or 1

          -  other

        Exclusion Criteria:

          -  metastatic CNS disease

          -  ocular or mucosal melanoma

          -  immunodeficiency

          -  splenectomy

          -  other
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Hersey, MBBS, DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>Conjoint Professor, Newcastle Mater Misericordiae Hopital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Melanoma Unit, Mater Misericordiae Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <lastchanged_date>September 12, 2007</lastchanged_date>
  <firstreceived_date>October 7, 2005</firstreceived_date>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Coxsackievirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
